Stem Cell Advisor

Exosome is another recent buzzword in the wellness and regenerative medicine space. Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. In recent years, exosomes have gained attention as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients. With at least  more than 23,000 scientific articles  published about exosomes and  more than 250 clinical trials underway , these small vesicles have intriguing potential to be used within a range of therapeutic applications. The term “exosomes” has become an increasingly common Search Term on Google over the past 10 years. Despite this flurry of activity, exosomes are coming under increasing scrutiny, with a Public Safety Notification on Exosome ...

At first, the trend was subtle. But, the tide has swelled and created a craze for promising CAR-T product candidates. Driven by approvals of the CAR-T products Kymriah and Yescarta, there has been a rush to chase the next CAR-T success. CAR T-cell therapy (Chimeric Antigen Receptor T-Cell) is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.” The global CAR T-cell therapy market size was valued at USD 2.75 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of  23.32%  from 2023 to 2030. Remarkable success in treating blood cancers, such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) has increased the adoption of CAR T-cell therapy and is anticipated to boost the industry's growth ( Grand View Research ). This article p...